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ABSTRACT
This thesis investigates the feasibility of using a complex model with a Monte Carlo simulation
model to forecast the financial, personnel, and manufacturing capacity resources needed for biologic
drug development. Accurate forecasting is integral across industries in order to make strong long-
term, strategic decisions and an area many companies struggle with. The resources required for the
development of a biologic drug are especially hard to estimate due to the variability in the time and
probability of success of each development phase. However, in the pharmaceutical industry getting
products to market faster allows the company more time to recoup the substantial development
investments before the patent expires and also potentially has a large impact on a company's market
share.
For these reasons, Novartis Biologics wanted to develop a simulation model to provide an objective
opinion and assist them in their long-range planning. This thesis describes the design, development,
and functionalities of the resultant model. During validation runs, the model demonstrated accuracy
of greater than 90% when compared against historical data for headcount, number of campaigns,
costs, and projects per year. In addition, the model contains Monte Carlo simulation capabilities to
allow users to forecast variability and test the sensitivity of the results. This proves the model can be
confidently used by project management, operations, and finance to predict their respective future
resource needs.
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1 Introduction and Overview
1.1 Problem Statement
The resources required for the development of a biologic drug are hard to estimate due to the
variability in the time and probability of success of each development phase. The biotech company
Amgen states that only one in ten new drugs that makes it into human testing actually makes it to
market [1]. A recent study by the consulting firm Bain and Company reported that the cost for
discovering, developing and launching (incorporates marketing and other business expenses) a new
drug (along with the prospective drugs that fail) rose over a five year period to nearly $1.7 billion [5].
Decisions on questions such as capacity and personnel expansion in the form of updating existing
facilities, breaking ground on new facilities, or striking a strategic partnership must be made years in
advance despite limited means for predicting future needs.
1.2 Motivation
The motivation behind the project is that the Novartis Biologics group wants to expand its capacity
to handle the increasing number of biologic projects. Previous LGO work provided the group a
means to forecast personnel requirements amongst sites but an evolving division rendered the tool
out of date with current site capabilities and division structure. In addition, the group needed a tool
to accurately forecast cost requirements. A model with costing functionality will give a more
complete picture, gain the confidence of the financial arm of the organization, and therefore help
the organization to make important strategic recommendations to senior management.
1.3 Hypothesis
I believe I can integrate financial information, site capabilities, and development step personnel
requirements to successfully model headcount and capacity and financial needs. This information
can be presented in such a way to aid in long-term strategic decision making.
1.4 Goals
From a macro perspective, my project is designed to be an analytical resource and personnel
planning tool. The drug development timeline is very long and the organization struggles to plan for
projects five - ten years down the road. From a micro perspective, my project is designed to weave
planning through the many sites and organizations that comprise biologics development. The final
model should forecast 1) full time equivalent employees across functional groups across product
types, 2) manufacturing capacity and site allocation, 3) product campaigns, and 4) financial
resources. A robust model should also provide a forecast range and associated probability of
occurrence.
1.5 Results
During validation runs, the model demonstrated accuracy of greater than 90% when compared
against historical data for headcount, number of campaigns, costs, and projects per year. In
addition, the model contains Monte Carlo simulation capabilities to allow users to forecast variability
and test the sensitivity of the results. This proves the model can be confidently used by project
management, operations, and finance to predict their respective future resource needs.
1.6 Thesis Overview
This thesis is organized into five chapters. The first chapter presents an introduction to and
overview of the thesis and its contents. Chapter two provides background on the pharmaceutical
industry, the drug development process, biotechnology, and Novartis. The third chapter dives into
forecasting, common forecasting techniques, Novartis' forecasting method, and pharmaceutical risk
hedging. The fourth chapter presents the specifics of the model by explaining the input, outputs,
and functionalities of the two key components of the model. In addition, chapter four discusses
dealing with uncertainty and the outcomes of the model validation. Finally chapter six summanizes
key findings and conclusions.
2 Company Background
2.1 Industry Overview
The goal of the pharmaceutical industry is to discover, develop, produce, and sell therapeutic drugs
to mitigate patients' diseases and symptoms. Though the dollar amounts quoted vary, bringing a
therapy to market from idea inception costs over $1 billion and takes 10 - 12 years to go through
development and regulatory approval. A recent study by the consulting firm Bain and Company
reported that the cost for discovering, developing and launching (incorporates marketing and other
business expenses) a new drug (along with the prospective drugs that fail) rose over a five year
period to nearly $1.7 billion [5]. This statistic integrates the attrition over the development period.
Amgen states that only one in ten new drugs that makes it into human testing actually makes it to
market [1]. Drugs are stopped along the development process for a litany of reasons. The most
common reasons are poor clinical results and toxicological and safety concerns. In addition, drug
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development is occasionally halted when a competitive product reaches the market first and the
market is deemed saturated.
Pharmaceutical Research and Manufactures of America (PhRMA) identifies five major trends
changing the industry: "increased complexity of the research and development process; continued
investment in Research and Development; increased use of medicines in health care; increased value
for today's patients; and continued importance of patent incentives for innovative medicines" [10].
2.1.1 Drug Development
The development and bringing to market of a new entity can be thought of in two distinct phases:
Drug Discovery and Drug Development. Drug discovery is the process by which NMEs are
discovered or designed. Drug development is the process that results after a NME has been
identified as a potential drug to turn it into a market viable product. This process converts a
complex, small-scale, and unsafe procedure from the laboratory to an efficient, large-scale, and safe
process that can be commercially manufactured. Drug development does not produce material that
is available for sale.
The drug development phase involves several phases of clinical trials to ascertain the safety of the
drug and determine appropriate formulation and dosing. There are generally three distinct steps: a
pilot plant campaign, a medium-sized manufacturing campaign, and a full-scale validation campaign.
The purpose of the campaigns is twofold. Every campaign produces three to five batches of
material that is used in clinical trials. In addition, the material yielded through the campaigns
undergoes rigorous quality testing and the campaigns themselves test process design and
improvements. At least one of the full-scale validation campaigns must occur at the final production
site of the drug because regulatory agencies approve specific manufacturing processes at a plant.
Players in the pharmaceutical field combat the high failure rate in a variety of ways. Large
multinational corporations are often vertically integrated and control all aspects of drug discovery
and development. The high cost of late stage development which is very capital intensive has led
many smaller companies to focus on one or two phases of the process such as formulation.
2.1.2 Biotechnology
Today, the pharmaceutical industry can be broken into two classes of therapeutic drugs: small
molecule therapeutics and biologic therapeutics. Small-molecule therapeutics such as aspirin are
composed of chemical compounds and are synthesized. Biologics are derived from living organisms
and include proteins, DNA vaccines, monoclonal antibodies, and peptibodies. They are
manufactured inside living cells in a more complex process than the traditional chemical synthesis.
The manufacturing equipment required for these classes of drugs varies greatly and equipment
cannot be shared between these two processes.
Hungarian engineer, Karl Ereky, coined the term biotechnology in 1919 to describe the interaction
of biology and human technology. The United Nations Convention on Biologic Diversity defines
biotechnology as "any technology application that uses biological systems, living organisms, or
derivatives thereof, to make or modify products or processes for specific use" [1]. The industry
took time to get off the ground from the days of Ereky. The first FDA approved biologic medicine
was human insulin in 1982 made via recombinant DNA technology [1]. Modern biotechnology
often focuses on understanding the metabolic pathways related to a disease state or pathogen and
how to effectively manipulate these pathways using molecular biology or biochemistry.
2.1.3 Biotechnology vs. Small Molecule Therapeutics
Figure 1 below summarizes the key differences between biologics and small molecule therapeutics.
Figure 1: Biologics vs. Small Molecule Therapeutics
Key Differences Between Biologics (Large Molecule) and Small Molecule
Drug Charateristics Target Side Effects Manufacturing
Dosed weekly - monthly Mostly outside of cells Rare due to low off Challenging
Intensive assay development Good at protein interactions target toxicity Causes large investments
Small Dosed hourly - daily Any druggable target More frequent due
Molecule Variable intake Enzymes / receptors / to action on / in Easier compared to Biologics
Standard assays channels multiple pathways I
Biologics have the potential to be more patient friendly than small molecule therapeutics. Because
biologics are more selective and specific, as they "attack" they only target the intended disease and
do not affect healthy tissues or cells; they typically produce fewer side-effects than traditional small
molecule therapeutics. Biologics are proteins and as such are degraded exactly the same way as
other proteins in the body. In addition, the long half-life of biologics leads to less frequent
administration. The therapeutic antibody activity can remain effective for 2 to 4 weeks [6].
2.2 Novartis Overview
2.2.1 Background
Novartis AG is a diversified healthcare company consisting of four divisions: Pharmaceuticals,
Vaccines and Diagnostics, Sandoz (Generics), and Consumer Health (Over the Counter, Animal
Health, and Ciba Vision). Novartis was created in 1996 with a merger between the Swiss companies
Ciba-Geigy and Sandoz. The company's mission statement is "to discover, develop and successfully
market innovative products to prevent and cure diseases, to ease suffering and to enhance the
quality of life [9]."
Novartis is headquartered in Basel, Switzerland with 119, 418 employees spread across 140 countries
around the globe. Novartis posted $50.6 billion in net sales and $10 billion in net income for 2010
[8]. Novartis plows a large portion of its revenue back into research and development (R&D) with a
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total expenditure of $8.1 billion in 2010. Pharma AG (the pharmaceuticals division) is the largest
division and generates the most revenue with net sales of $30.6 billion in 2010. Currently their
portfolio of patented prescription drugs contains over 50 key marketed products. A number of
these products are leaders in their field including cardiology, neuroscience, oncology, and
respiratory.
In 2009, Novartis received over 25 positive regulatory decisions in the United State, Europe, and
Japan. In addition, their product development pipeline has 147 projects in a litany of stages of
clinical development. While historically small molecule pharmaceuticals have been a very successful
area for the company, they are also expanding into biologics.
2.2.2 Biologics Group
The Novartis Biologics Group (NBx) launched in 2007 is the large molecule drug development
group and is within the development division of Novartis Pharma. NBx is a small but growing part
of the Novartis organization comprised of about 550 employees in Switzerland and the United
States. For the past two years, the NBx group has been growing strongly at 33% a year. The
organization has a strong track record of delivering medicines to patients. At present, biologics
represent a quarter of the overall Novartis research and development pipeline [6]. Novartis'
Biologics pipeline ranks in the top five in the industry behind Roche, Pfizer, and Amgen.
NBx is responsible for biologic projects from protein or antibody design up through the completion
of Phase II of clinical development. In addition, the group also provides support for biologic
projects during later stages of development and commercial production. Biologics development is
governed by three different organizations: Sandoz, Novartis PSP (Process Science Production), and
Novartis BPO (Biologics Pharmaceutical Organization). Sandoz operates several biologics facilities
that are designated for future use in developing and producing biosimilars.
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The immediate Novartis owner of this project, Philippe Marschal is in charge of operations for the
Novartis Process Sciences and Production (PSP) organization. The PSP group is responsible for
process development and production across four groups: Process Sciences, Clinical Manufacturing,
Quality Control, and Project Management. The figure below shows the organizational makeup of
the Biologics division.
Figure 2: Biologics Organizational Makeup
Ue
-.
NBx has four main products:
" Biosimilar cell culture - generic version of a drug that is nearing patent expiration and is
produced using mammalian cell culture
e Biosimilar microbial - generic version of a drug that is nearing patent expiration and is
produced using microbial expression systems
e Microbial - NMEs produced using a microbial expression system such as E. coli or yeast.
This manufacturing method requires different manufacturing steps and different equipment
than cell culture products
e Monoclonal Antibody - antibody produced by cells that are all derived from a single
antibody-producing cell. Once a cell capable of generating an antibody with desired
therapeutic characteristics is selected, laboratory processes are used to clone (make large
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numbers of) these cells. Since the cells are all identical and can be used to continuously
produce identical antibody molecules with these same therapeutic characteristics [1]
Figures 3 and 4 illustrate the development differences at Novartis between New Molecular Entities
and Biosimilars [11].
Figure 3: New Molecular Entity (cell culture and microbial) Development Path [14]
-Early Process
Development
-Manufacture
product for
Toxicology
Studies
eRobust *Manufacture *Process -Manufacture *Preparations *Process
Product product for Development/ product for for Validation
Development Phase 11 Scale-up Phase il commercial
-Manufacture Clinical Trials Clinical Trials manufacturing
product for
Phase I
Clinical Trials
eRegulatory
Submission
Figure 4: Biosimilar (biosimilar cell culture and biosimilar microbial) Development Path [14]
*Early Process *Robust *Manufacture ePhase I Trials *Phase I Trials -Preparations eRegulatry *Product
Development Product product for for Submission Launch
Development Phase I Clinical commercial
-Manufacture Trials manufacturing
product for * Product
Preclinical Validaion
studies
2.3 Organizational Assessment: Three Lens Analysis
Dr. Bela Banathy developed an approach to analyze organizations using three types of interrelated
models to give a multi-dimensional view he coined the Three Lenses. His model is comprised of
the strategic design, cultural, and political lenses [15].
2.3.1 Strategic Design
The strategic design lens examines how the flow of tasks and information is designed, how people
are sorted into roles, and how the roles are related. Ultimately this lens demonstrates how the
organization can be rationally optimized to achieve its goals [15].
The basic strategy of the organization is to heavily ratchet up the number of projects in the Novartis
Biologic pipeline. At present, biologic drugs at Novartis make up 25% of projects in the overall
company pipeline. This represents a significant increase and is directly related to this project
because biologic development is an unknown.
Novartis is a company with very independent divisions. Thus jobs are designed with one particular
organization in mind. This factor makes doing a project with stakeholders in three separate and
sometimes diverging divisions a challenge. Similar to most large companies, collaboration between
divisions could be significantly improved.
2.3.2 Cultural
The cultural lens examines how history has shaped the assumptions and meanings of different
people and how certain practices take on special meaning and even become rituals. In additions,
this lens analyzes how stories and other artifacts shape the feel of an organization [4].
The project is related to basic organizational assumptions and levels of acceptable risk. The project
process and ultimate output will either change or reinforce these commonly held beliefs. Due to the
project duration, management is hesitant to tout potential results without having a finished model.
The symbolic meaning of the project for the organization is that the resultant model will be
representative of recent organizational changes. The MIT name also has an interesting symbolic
meaning at Novartis. Due to the heavily publicized continuous manufacturing project and support
from top management, the MIT name is very visible and highly revered. This adds a certain amount
of pressure to perform on internship work.
There are anticipated different sub-cultural responses to this project. The BPO organization in the
chart above has been largely absent from the project. The finance arm of Novartis PSP has
diverging interests from the operations arm which has diverging interests from the entire Sandoz
organization. The best cultural lever for getting this model accepted across stakeholder groups is to
brand it as the MIT model. By introducing the model from an outside perspective, we hope to
remove some of the political issues and more easily gain widespread use.
2.3.3 Political
The political lens examines how power and influence are distributed and wielded, how multiple
stakeholders express their different preferences and get involved in decisions, and how conflicts can
be resolved [4].
Stakeholder interests vary widely and are not always compatible. The finance arm of the
organization wants a tool that pinpoints areas of financial waste that can ideally be eliminated or
heavily reduced in the future. In addition, the finance arm wants a tool that can make the budgeting
process less painful. The operations arm wants a tool that accurately predicts resource needs
amongst sites many years down the road and helps save money from an operations perspective. At
the end of the day, all stakeholders want to have an accurate and reliable tool that forecasts resource
and personnel needs.
The biggest source of power is the operations arm of Novartis PSP. Sandoz seems to have less
power as an organization than Novartis across the board. Sandoz largely makes generic drugs with
significantly lower margins. Their facilities pale in comparison to those of Novartis and they seem
to be spoken of as second-class citizens. However they play an integral role in biologics
manufacturing and will be likely producing the final products. They may gain more power with the
model. There are no formal measures to allow less powerful parties to voice their interests.
3 Forecasting Procedures
3.1 What is Resource Forecasting?
All companies employ forecasting methods whether it is estimated demand for their specific goods
and services next week or ten years from now. Having a robust forecasting system is imperative to
resource planning and allocation - personnel, product, raw materials, and physical space.
Companies use demand forecasts to make strategic decisions that they often will not realize the
effects of for years down the road. In addition, forecasting helps companies identify where gaps
exist between their desired state and their most probable state. Knowing their potential future
shortcomings allows companies time to make changes before the shortcomings hit.
3.2 Common Forecasting Methods
Forecasting can be broken down into two distinct methodologies: 1) Manual Forecasting and 2)
Simulation. The historical method, manual forecasting, is a very time consuming process by which
specific functional groups provide estimates for a specific occurrence. An example of this would be
all the sales representatives in a region estimating the sales volume for their territory for the
following year. These figures would roll-up by region into corporate sales which would then make
an estimate on sales volume for the company for the following year. With this figure, other groups
within a company would be able to plan for personnel, production, etc. Manual forecasting is only
as accurate as all the aggregate pieces of information collected. It is slow, very time consuming, and
challenging to alter if situations change such as the slow-down of the economy or a new competitive
entrant into the market.
Most companies have been transitioning to the second school of thought in forecasting: simulation.
This thesis focuses on simulation. The first component of simulation forecasting is developing a
robust model. There are many off the shelf models available or companies can develop them in-
house. Modeling uses historical data, market data, experimental design, and equations to calculate an
expected outcome given a set of assumptions. Then the simulation varies the assumptions to
provide a complete picture of future scenarios.
3.3 Pharmaceutical Risk Hedging
The long time period and inherent uncertainty of drug development described previously makes
resources forecasting all the more important for the pharmaceutical industry. Computer modeling
has been picking up steam in the pharmaceutical industry as companies realize the intrinsic value of
using simulations for drug development and capacity planning decisions. In his book James Stahl, a
healthcare modeling expert, states that models and simulations are used for the following reasons in
pharmaceuticals: 1) To test something that is impossible to test through direct experimentation, 2)
To better understand or predict the outcome of a complex system, and 3) To aid in decision making
[13].
The key drivers for the pharmaceutical industry are manufacturing capacity and skilled personnel.
Due to the lengthy regulatory approval process, additional manufacturing capacity often takes
upwards of five years to design, build, test, validate, and gain regulatory approval in order to be
commercially viable. David Ebersman of Genetech explains "Some of these phases could overlap if
we wanted to compress the schedule, but it would be difficult to complete a plant successfully in less
than four and a half years. There are thousands of process steps and 100% process control and
sterility are required [12]." From a personnel perspective, employees are highly skilled and it can
take a year to find qualified applicants, take them through the hiring process, and provide them the
necessary substantial training.
The high capital investments and lengthy process of building an FDA-approved manufacturing
facility makes accurate long-term modeling very important for the long-term success of
pharmaceutical companies. They cannot afford to delay drug development while waiting for new
plants to come online but also cannot afford to let plants and operators sit idle if the huge variations
in anticipated capacity end up on the lower end of the slope. In addition, the FDA requires new
licensing to reengineer part of current production processes. David Ebersman of Genentech
explains the ramifications of regulations. "When the FDA approves one of our drugs, they are
approving the drug in the context of a specific manufacturing process in a specific location. If we
tweaked any of the raw materials or process steps, we might need to go through the entire approval
process again. That would entail stopping production and running tests again and again until we
could prove that the product produced using the new process is identical to the original version that
was tested with patients in clinical trials. If we saw any discrepancy, we might need to test the new
version with patients, which could take several years [12]."
Ebersman's explanation of regulatory ramifications shows why pharmaceutical companies have
attempted to develop ways to hedge risks. Because new facilities are very capital intensive and take
up to five years to become fully operational, many pharmaceutical companies choose to outsource
both development work and manufacturing to a Contract Manufacturing Organizations (CMO).
These CMOs hedge risk for individual companies by building industry capacity in lieu of individual
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companies building solo capacity which may outstrip their specific demand [2]. However there are
downsides to contract manufacturing. Outsourcing is almost always more expensive on a per man-
hour basis and requires time and internal resources. Additionally, in order to build a successful
relationship with the CMO, the pharmaceutical company needs to share some of their production
expertise with the CMO which may equate to building a future competitor.
3.4 Novartis' Forecasting Method
Prior to 2009, Novartis used a manual forecasting method. Novartis has a project management
software program called SUCCEED that tracks each project's current status and costs. Each year
the unit heads would use that information and apply a standard template to evaluate their needs for
the coming year in terms of FTEs and resources. They made manual deviations from the template
based on their own knowledge of the technical difficulty of each project, current delays, and
projected future delays. Then management used these figures to construct three scenarios:
1) Stay flat
e Keep current number of FTEs
e Reshuffle FTEs as needed amongst funded projects
2) Stick to strategic plan
3) Support all products in pipeline
* Might entail adding capacity and resources or making substantial investments
After defining the above scenarios, management would research each scenario and overlay it with
the projected pipeline to determine the financial liabilities and benefits. This investigation involved
looking at each scenario from both a bottom-up and top-down perspective. The bottom-up vantage
point culminated in submitting all scenarios to upper management and the head of development
finance. The top-down approach took the goals that were handed down from corporate finance and
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synthesized them into the most likely scenario. To plan for the coming years, Novartis would take
the chosen scenario and age it over multiple years with industry attrition rates.
Though the methodology described above is appropriate for keeping track of each project's status
along the drug development process, it is very time consuming with many non-value added
components and does not adequately take into account risk. Novartis does have two key
advantages in hedging risk: 1) The Sandoz division, and 2) Strong relationships with CMOs. Sandoz
is Novartis' generic division which also develops biosimilars and has excess manufacturing capacity.
Realizing their shortcomings and potential areas for improvement, Novartis Biologics brought in
LGO student Tamara Conant in 2008 to examine their forecasting process and suggest
improvements. Tamara designed and constructed a model to forecast full time equivalent
employees or FTEs. This model is described in full in her thesis Modeling Variability for Biologics
Strategic Planning [3]. In 2009, Novartis Biologics brought in LGO student Angela Thedinga to
continue Tamara's work. More detail on this can be found in her thesis Forecasting Resource
Requirementsfor Drug Development Long Range Planning [14].
4 Model Methodology
4.1 Model Goal
This model is intended to assist with five year strategic planning and strategic decision making (i.e.
capacity expansion and outsourcing decisions) by estimating:
e Headcount
e Manufacturing Capacity
e Financial Resources (Internal and External)
for NBx TSS, NBx PSP and BPO development. A robust model should also provide a forecast
range and associated probability of occurrence. The model should be simple enough to be used by
personnel across the organization with minimal training.
4.2 Approach
I began the project with the aim of utilizing information from different areas of Novartis to design
and construct a comprehensive resource, project and financial forecasting, and long-range planning
model. There were seven major tasks associated with the project:
1) Baselining the current state of doing resource, project and financial forecasting, and long-
range planning.
2) Determining the strengths and areas for improvement of the current model
3) Designing a future state model
4) Collecting data
5) Incorporating the data into the future state model
6) Validation
7) Creating a system for keeping the model up-to-date and relevant
The following sections will detail the culmination of this approach.
4.3 Model Description
The resultant model is comprised of two files: the front facing model and the back of the house
work package. The reason behind this split is twofold. First, as the amount of data entered into the
file grew during model design and construction, the file took an increased amount of time to process
and crashed frequently. Splitting the work package and user dashboard dramatically decreasd
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involuntarily Excel shut-downs. Secondly, the work package file contains the bulk of the
assumptions and corresponding data. This data should not be changed unless there is a specific
change to part of the drug development process i.e. a new step, productivity increases, etc. The
actual model file is where the user enters inputs and views outputs.
4.4 The Workpackage
The workpackage assumes that each project can be described by one of seven "standard" project
templates. The seven templates are mAb 3 step, mAb 2 step, microbial, mAb biosinilar, microbial
biosimilar, vaccines/3rd party, and external. These seven templates define the headcount, materials
and services, and campaign requirements considering all tasks required for a single project.
Within each of the seven templates is a list of tasks that need to be performed to take a drug from
idea conception to readiness for commercial manufacturing. These standard platform activities
were decided upon by the group heads in each of the various departments. Tasks were then
bucketed into the following groups of Development and Operations activities: Process
Development, Analytical Development, Drug Substance (DS) Production, Drug Product (DP)
Production, Quality Control, Formulation, Toxicology, IBP Cell Culture, IBP Microbial, and Project
Management. A few examples of developmental and operational activities are below:
* Manufacturing of non-GMP tox material - Product Development
* Cell line generation initial stage - IBP Cell Culture
e Tissue cross reactivity study (Monkey, Human, Mice) - Toxicology
" Virus validation study - Product Development
The list of activities varied slightly depending product family. For example, the mAb 3 step template
lists 155 activities while the microbial template lists 147 activities.
Each activity is listed with the total number of associated working days, external cost in dollars,
number of campaigns, group, and site. The developmental timeline shown below is used to specify
activities for each project into a certain time period. The duration of time a project spends in each
stage of the developmental timeline can be altered as the process efficiency increases.
Figure 5: Development Stage Definitions
Development Stage Defin itions
mAb/microbial activities | biosimilar activities I vaccines/3rd Dartv activities
The total number of working days needed for each activity is then allocated to a cell(s)
corresponding to the specific quarter(s) along the development timeline. The external cost and
number of campaigns are allocated to a cell (s) corresponding to the developmental year in which
the cost hits Novartis' budget.
4.5 The Model
The model contains a litany of color-coded tabs. The color key below is intended to help the casual
model user with model operation.
Figure 6: Model Color Key
Color Key
4.5.1mod Information about the model and its use.
Uer Inus Inputs specified by the user.
Cr-st,1,.8I IpuqJInputs defined through Crystal Ball. When a simulation is run, these cells change
Outputs or reports generated by the model.
Assumptions IThese tabs define the underlying assumptions and calculations and are normally hiddn
4.5.1 Model Assumptions
The model assumptions are integral to its operations and accuracy. Assumptions should be
reviewed and updated annually or with any large business changes. The model contains both fixed
and flexible assumptions.
The fixed assumptions are primarily found in the workpackage and cannot be changed without
significantly changing the model structure. Fixed assumptions include:
e All projects are assumed to be represented by a "standard" project, requiring an average
number of resources (FTEs, manufacturing capacity, and financial resources).
e The resources required for a "standard" project this year are assumed to be the same
number of resources required for that type of project for the next ten years. No
organizational efficiency (or improvement over time) is factored into the model.
* All employees within the same functional group at any site are equally capable of working on
any type of project, and each employee can work on an unlimited fraction of projects. Each
FTE is only limited by the number of work days in the year.
e Manufacturing sites are interchangeable and campaigns are assigned per the site allocation
defined by the user.
" Activities in the next stage can only be started when all of the tasks in a previous stage are
complete.
e The progression of projects through the pipeline is fractional, not discrete
e Fractional projects are added, so four projects that all have a 50% chance of progressing are
considered as two full projects
e The organization is split into a defmite number of groups and will remain that way for the
period of the forecast (model does not predict organizational structure changes).
* The model assumes that for each simulation run, each development stage takes the same
amount of time for all new molecular entity or biosimilar projects. For instance, if the
simulation generates a 1.5 year duration for development stage 4, then all projects will take
1.5 years to complete stage 4 for all ten years of the forecast.
" No matter what the phase duration time is, the work required for that development stage is
spread evenly over the years required to complete the work.
e The model assumes that all future projects will start in development stage 1. This is not the
case for many in-licensed projects. Currently in-licensed projects can be considered by
assigning the appropriate development stage to the current project parameter, but all future
projects are assumed to enter the pipeline at development stage 1[14].
Many of the flexible assumptions double as the model inputs and can be changed easily based on
changes in the business. These inputs will be detailed in the next section however there are a few
key flexible assumptions that likely will not be changed by the casual user including:
e Resources required per development stage and per functional group
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e Time required for each development stage
" Number of manufacturing weeks for each campaign broken out by development phase
" Working days per FTE
One FTE works 250 days a year. After accounting for 25 days of vacation, sick leave,
training, and administration, we assume that an FTE spends on average 80% of those 250
working days on project work. This equates to 1 FTE = 200 days of work.
* Inflation rate
* Exchange rate of the US Dollar to Swiss Franc and Euro
4.5.2 Model Inputs
The model inputs are listed below:
1) Current Projects - listing of projects and current development status, located on the
"Current Projects" worksheet
The current projects are broken down by the development timeline illustrated in Figure 5.
Projects can be listed as fractions totaling one across two development years depending on their
progress. Occasionally due to limited resources, a delayed project will only show as a fraction of
a project.
2) Future Projects - estimates of future new projects with a probability distribution, located
on "Future Projects" worksheet
Figure 7 below shows the target for incoming projects by calendar year spread amongst the
seven product categories. All data is fictitious. The Novartis model owner will update these
figures based on corporate goals and R&D projections.
Figure 7: Future Projects Snapshot
Incoming Projects
microbial mAb Vaccines/
mAb - 3 step mAb - 2 step microbial external biosimilar biosimilar 3rd Party
Year Target Target Target Target NBx Total Target Target Target Grand Total
2010 2.5 1 0.5 1 5 0 1 1 7
2011 3 3 1 2 9 0.25 1 2 12.25
2012 4 4 1 3 12 0.25 2 3 17.25
2013 4 2 2 3 11 0.25 2 1 14.25
2014 3 5 2 3 13 0.25 1 2 16.25
2015 3 3 2 2 10 0.25 2 3 15.25
2016 2 4 3 3 12 0.25 3 3 18.25
2017 4 5 3 2 14 0.25 1 2 17.25
2018 2 7 3 3 15 0.25 2 2 19.25
3) Probability of success between development stages - fraction of projects that progress
from one development stage to the next, located on the "Future Projects" worksheet
For each of the seven different defined product types, a probability of success is defined. An
example of this for biosimilars and vaccines is shown in Figure 8 below. For the technical
development step, it will most likely take three years. However there is a possibility of this step
taking between two and four years. These probability distributions are used in the Monte Carlo
simulations which are detailed later in the Uncertainty section of this document.
Figure 8: Biosimilar and Vaccines Probability of Success
biosimilar and vaccines likeliest min max
TechDev/Preclinical 2.00 4.00
Phi 1.00 3.00
PhIll 1.00 3.00
Submission 1.50
Total 8
4) Percent of projects performed at risk - percentage of projects that will process to the
next development stage without pass/fail indication, located on "Future Projects" worksheet
Due to the limited patent life of a new product and the long development time line,
pharmaceutical companies such as Novartis try to accelerate development activities to bring
33
products to market sooner to recoup the high costs of development. Companies do not want
any delays in clinical trials due to waiting for test material, manufacturing development, etc.
Most products follow the steps of development process in the chronological order detailed in
Figures 3 and 4 depending on the product type. However at times, management may choose to
perform some activities before the preceding activity is complete.
For instance, the results of a clinical trial either kill a project or push it further along the path of
becoming a commercially viable product. Continuing along the development path without
knowing the clinical outcome is precarious because development is proceeding at risk of a
negative outcome. Thus these activities are said to be done at risk. If the product fails the
clinical trial, these activities done at risk are a waste of resources that could have been better
spent elsewhere. If the product excels in the clinical trial, then having already performed some
of the activities in the next developmental step lessens the time until the drug can be introduced
into the market. Getting products to market faster not only allows the company more time to
recoup investments before the patent expires, but also potentially has a large impact on market
share. Figure 9 below shows the percentage of activities performed at risk by product family.
Figure 9: Percentage of Activities Performed at Risk
% at risk mAb - 3 step mAb - 2 step microbial
Year 2 activities performed at risk 50% 80% 80%
Year 3 activities performed at risk: Mainly
Phase 11 supply 50%X 80% 80%
Phlll Dev. Activities Performed at Risk
before POC readout 25%, 25% 25%
PC/PV Activities Performed at Risk 10%/ 1 0% 10%
5) Site Alloc ation - resources -required are categorized into Competence Center (CC),
Development Site (DS) or Launch Site (LS) activities. The proportion of these activities per
site is defined in the "Site Allocation" worksheet.
Some functional groups are only located at one site and thus some activities must always be
performed at the same site. These resources are defined as "fixed". Other activities could be
sourced by different site (i.e. mAb development site activities could be performed by Basel or
Kundl) and are defined as "flexible". Manufacturing campaign site availability depends on the
capabilities of the various manufacturing sites, the product type, and the product development
stage. The site allocation dictates the proportionality of the flexible activities.
Figure 10 is a snapshot of the site allocation for 2010. The grey cells represent a non-match
between a site's capabilities and the drug type. The orange cells show potential sites where a
project can be slotted based on drug type and needed development activities. Site allocations
can be allocated manually by percentage or can be left blank for the model to find the most
efficient allocation. For instance, 40% of the development activities performed in 2010 for the
mAb 3 step product will be done in Basel and 60% will be done in Schaftenau.
Figure 10: Site Allocation for 2010
2010
Drug Type 'Center
mrb pat DS 'Ab3DS 0 0
LS CmiC
m Crnb Cb10
Bismar micb S0
MicrobialDS S
rdpimar - --I80-0
iLS |vaL 100% 0%
6) FTE Adjustments - a listing of all resources required that are not considered in the project
assumptions for various reasons (i.e. Future LCM activities, plant support not proportional
to number of projects, etc)
The FTE adjustments represents a small number of resources needed that fall outside of the
platform process activities detailed in the workpackage. A 2010 example of an activity in this
section was Copaxone bioanalytics for toxicity clinics. For 2010, the FTE adjustments section
resulted in the forecasted addition of less than ten people.
4.5.3 Model Calculations
Once all the inputs described previously are entered, the model is able to begin calculations and does
so without prompting each time data is added or updated. The output of the workpackage is a
matrix of activities by quarter that can be summed to find headcount per quarter, external costs by
development year, and campaigns by development year. This can then be simplified into a matrix of
headcount, costs, and campaigns by phase by group. The gray calculation tabs in the model pulls in
the resultant matrix of information from the workpackage.
One important component of model calculations that is not represented in the workpackage is
headcount costs. Personnel costs are listed in the gray "Financial Template" tab in the model.
Listed here are the average yearly salaries of employees in specific groups in specific sites. An
example of such a group is process development employees located in Menges. In addition, other
costs proportional to FTEs such as travel and training costs are listed here.
At a high level, the following calculations generated the output data for the model:
e Number of future projects in a given year = Current projects * Future projects * Probability
of success that a project progresses * Time factor * At risk factor
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e Total working days = Number of projects by development phase * Corresponding sum of
working days per total development phase activities * Probability of success that a project
progresses * Time factor * Headcount for current phase * At risk factor
e Total FTEs Cost = FTEs per group per site * (corresponding personnel costs per group per
site + miscellaneous costs per FTE when applicable)
" Total Material and Services Cost = Number of projects by development phase *
Corresponding Materials and Services costs by development phase
" Total Costs = Total FTE Cost + Total Material and Services Cost
4.6 Model Outputs
The model outputs were designed to be easy to read, comprehend, and use by the key stakeholders.
The core outputs are shown below:
e FTE Summary - FTEs required per site per group per year, located on the "FTE
Summary" worksheet
Figure 11 illustrates a potential headcount projection across two sites, Basel and Huningue, for the
mAb product type for the current year until 2018. The headcount is broken down by functional
group eg Process Development, Analytical Development. The Huningue site is focused primarily
on cell culture and thus does not have the capability to perform activities bucketed into a number of
functional groups such as Toxicology. Thus the projected headcount for Toxicology for Hunigue
is zero. The model contains these detailed headcount projections for each product type by
functional group across all applicable Novartis sites.
Figure 11: m-Ab Headcount Projections
FTF Fnretn-tq
These FTE summary tables were well received by management and have been useful in making FTE
projection charts for high-level resource meetings and the budgeting process.
Figure 12: FTE Projection Chart
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Additionally, a few stakeholders expressed interest in having the FTE information easily available in
less detail. Figure 13 below rolls up the all the individual group FTE forecasts and shows a
representative output of FTE forecasts across two sites, Basel and Huningue, for the seven different
product groups plus enabling technologies which is essentially an administrative function. Figure 13
was constructed in accordance with my sponsoring department's budget. A simple toggle switch on
the main headcount page results in Figure 13 which allows the group to gain a 30,000 foot view of
needed resources for budgeting.
Figure 13: Total Headcount Projections
FTE Forecasts
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* Campaign Summary - Campaign weeks per site required for development projects, located
in the "DS Campaign Summary" and "DP Campaign Summary" worksheets
The campaign summaries are broken down by Drug Substance and Drug Product. The resultant
tables follow the same format as the FTE summary. Figure 14 below gives a high-level view of
Drug Substance Campaign Forecasts for the Kundl site across the product family types. The most
important take away for the campaigns are the total number of campaigns in addition to the
campaign weeks. This is because different campaigns require different number of batches
depending on the size of the clinical trial. Producing additional batches requires additional
manufacturing weeks.
Figure 14: Drug Substance Campaign Forecasts - Total
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Figure 15 shows a more detailed output for the microbial product family in Kundl. Output tables
for Drug Product Campaign Forecasts look very similar.
Figure 15: Drug Substance Campaign Forecasts - Detailed
POutputh
Phase 1/Il Campaigns
- Phase Ill Campaigns
V-adation/Launch Oarnpaigne
Total Campaigns
iII bU c Phase 1/11 Campaign Weeks
Phase lIII Campaign Weeks
Vlidatio/Launch DP
Total Campaign Weeks
1 0 0 0 0 0 0 0 0
1 0 1 0 0 0 0 0 0
3 1 2 2 2 3 3 3 4
10 2 1 5 4 2 2 3 5
16 0 9 3 0 5 3 1 2
Total
73 171
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Another interesting functionality of the campaign forecasts is comparing the campaign forecasts
against manufacturing capability. A discrepancy in manufacturing capacity and projected need
merits the investigation into expanding capacity either through new construction, acquisition, or
partnership. As described in the pharmaceutical risk hedging section, many pharmaceutical
companies enter into relationship with CMO (Contract Manufacturers). Novartis has such a
relationship that allows them flexibility in dealing with the inherent uncertainty in drug development.
However, many of these contracts are multi-year and signed years in advance so an accurate forecast
is paramount to ensure that Novartis is able to fully utilize its own manufacturing capacity while still
fulfilling its contractual obligations to the CMO. An example of the PSP organization's
manufacturing capacity is shown in Figure 16 below.
Figure 16: PSP Manufacturing Capacity
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0 Financial Summary - Internal and External Costs per site, located in the "Total Costs" and
"Materials and Services Costs" worksheets
Financial transparency and granularity was a key model request by Novartis. I worked closely with
the unit heads to capture all costs associated with each step of the process. The budgeting process is
complex and very time consuming. Initially the model will be used to help the budgeting process
start off in the correct ballpark. As management begins gaining confidence in the model, usage of
the model has the potential to reduce the time taken for yearly budgeting by 90%.
Figure 17 shows a snapshot of the projected yearly costs of mAb product development in Basel by
functional group.
Figure 17: mAb Costs - Basel
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Figure 18 is a compilation of all the costs that hit the Process Science Production (PSP) budget.
mAb
Figure 18: Total Costs - PSP Budget
e Projects per year - matrices and charts describing the number of projects per development
year projected for the upcoming ten years, located by division in the "NBx PSP" and "BPO"
worksheets
The most visible output of the model is the projects per year. A project portfolio matrix is
calculated for each one of these project types and is easily used to create charts showing the
forecasted project pipeline.
An example pipeline chart is shown below in Figure 19. The pipeline charts are often used in
meetings to upper management.
Figure 19: Novartis Biologics Pipeline Projection
* Assumptions Summary - printable report of key assumptions, located in "NBx
Assumptions Summary" and "BPO Assumptions Summary" worksheets
The assumption summaries are broken down by division, Novartis Biologics and Biologic Process
Organization (BPO). Each summary details out headcount, pipeline, and development stage
assumptions. These assumption reports are meant to be a simple way to explain the logic of the
model to new users or management.
4.7 Uncertainty
This model uses a simulation tool to forecast a project portfolio matrix, and calculate the resources
required based on that matrix. However, most of the model inputs and even many of the fixed
assumptions carry an amount of uncertainty. For example, the future projects are listed up to ten
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years in the future. To combat this uncertainty while still allowing users to make long-term strategic
decisions based on model predictions, a Crystal Ball Monte Carlo simulation is incorporated into the
model. Crystal Ball is a software program from Oracle that has the ability to simulate a large
number of scenarios [7]. It accomplishes this by populating cells with randomly generated numbers
based off of user defined probability distributions. In this model, the simulation is run 1000 times
and the resource requirement outcomes are saved. These outcomes can be graphed and statistically
evaluated. This allows the user to understand the probability that a specific number of resources are
required and evaluate the sensitivity of assumptions.
Figure 20 below shows the model's predicted headcount forecast with a Monte Carlo simulation.
1000 trial simulations were run and both a high and low scenario was generated. The dashed lines
represent the number of FTEs needed in a 10% and 90% scenario.
Figure 20: Headcount Forecast
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4.8 Validation
Since any model is only as useful as it is accurate, testing is imperative. A forecasting model is
challenging to test since stakeholders do not want to wait to determine how close a model predicted
a future event. Instead, I chose to use historical data to back validate. Unfortunately Novartis
Biologics is a new organization and data is only available for 2008 and beyond.
To back validate, I entered in the current list of projects for 2008 and their corresponding
development stage. To replicate the pipeline projection at that point in time, I combed through
management presentations to determine what they intended for the pipeline to look like ten years
out. I also adjusted the structure of the model to replicate the manufacturing sites available and
their respective capabilities in 2008.
The resulting FTE, financial, and resource requirements and project pipeline for 2010 were then
compared to the actual. These figures ranged from 10 - 25% off of target. By reviewing the
discrepancies, I ascertained that the drug development timeline was longer in practice than in the
model. This meant that a project started in the beginning of 2008 that should have progressed to
development year 2.5 by the middle of 2010 was in reality only at development year 2.0. The
difference in the overall eight-year development process was approximately 1.5 years. This
discrepancy is not surprising since Novartis is still learning the biologics industry. Altering the
structure of the model to account for the new timeline led to a much tighter adherence. The
extended product development timeline resulted in a 2 - 9% match between historical projections
and actual data. Using historical data to back validate the model was repeated using 2009 inputs.
The resulting forecasts from the 2009 for the year 2010 matched 2010 actual data within 4 - 8%.
Though there are obviously limitations to using historical data for validation, the results of the
validation tests were important to iteratively improve the model and ultimately prove its accuracy.
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5 Recommendations and Conclusions
5.1 Conclusions
During validation runs, the model demonstrated accuracy of greater than 90% when compared
against historical data for headcount, number of campaigns, costs, and projects per year. In
addition, the model's Monte Carlo simulation capabilities allow users to forecast variability and test
the sensitivity of the results. This proves the model can be confidently used by project management,
operations, and finance to predict their respective future resource needs.
5.2 Recommendations
In order for any model to have long-term success, it must remain accurate, respected, relevant, and
easily usable. I would like to address each one of these challenges separately below.
1) Accuracy
Novartis Biologics is an organization in flux. While I was on my internship, the organization
went through several different rounds of structural change. Each round of changes had
some impact on the model. Even in a stagnant organization, processes are updated and
ownership changes hands. Since much of the model is structured to fit the context of the
current organization, future organizational changes will merit substantial model updates. In
order to address these concerns, I recommend reviewing the model each time structural
changes are made in addition to implementing a well-defined model review process. In
addition, it would be helpful to pull data in from SUCEED for short-term planning and
more frequent updates than the yearly meetings.
2) Respected
Model credibility and correspondingly respect was a key issue I encountered during my six
months in Basel. There is a certain uneasiness by most people to the unknown. So much of
the work of the model is done outside the view of the end-user. Model owners need to
work with end-users to ensure understanding and agreement with the core assumptions. In
addition, visual upper management support is crucial to credibility.
3) Relevancy
The ultimate goal of the model output reports, charts, and tables is to present the data that is
most helpful to key decision makers to aid them in strategic planning. In order to do this,
the model owners must foster close dialog with upper management and other key decision
makers to understand their needs, gain support, and increase the usefulness and thus value
of the model. Keeping the model relevant will also help it remain respected.
4) Easily Usable
The model is complex. It involves two different Excel files that must be used in conjunction
and a Crystal Ball Monte Carlo simulation if the user wants to incorporate variability and test
the sensitivity of analysis. At present, there are a handful of users who are model experts
and a few more who are able to use the model to generate charts and figures for
presentations. Some stakeholders mentioned wanting a robust model in a non-Excel
program. Though I investigated this option and Novartis' internal software building
capabilities, I ultimately ruled it out because the learning curve for a new software would be
too great for the casual user. In addition, the model complexity may become a hindrance to
its expansion into other applications. The volume of data and calculations in the current
model was sufficient enough to necessitate two partner files.
From an overall perspective, I recommend implementing a well-defined model review process to
review input data and key assumptions. This could take the form of an annual data review by the
model owners, unit heads, and other key stakeholders to ensure accuracy. By implementing a review
process and taking strides to address the key issues previously described of accuracy, respected,
relevant, and easily usable, the model will be able to assist Novartis Biologics in long-term resource
planning and allocation for the foreseeable future.
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Appendices
GLOSSARY
Biosimilar: a generic or follow-on biologic, either mAb or microbial
EMEA (European Medicines Evaluation Agency): the European regulatory agency established
to regulate the release of new foods and health-related products
FDA (United States Food and Drug Administration): the federal agency in the Department of
Health and Human Services established to regulate the release of new foods and health-related
products
FTE (Full Time Equivalent): amount of work equal to one full time employee
Microbial: protein-based molecules expressed in a simpler E. Coli or yeast cell, a type of biologic
therapeutic
mAb (Monoclonal Antibody): complex protein-based molecules produced in mammalian cell
culture, a type of biologic therapeutic
NBx (Novartis Biologics Group): formed in 2007, housed within Novartis Pharmaceuticals
NME (New Molecular Entity): compound or molecule that is patent protected
Phase I/POC/IIa: first clinical trials to explore the safety and tolerability of patients to a drug,
small patient population, shorter in length (Rang, 2006)
Phase IIb: clinical trial to confirm dose selection, larger patient population, longer time (Rang,
2006)
Phase III: clinical trial to confirm efficacy and safety to support registration, large patient
population, long time (Rang, 2006)
Probability of success: the chance that a drug candidate has to progress from one development
stage to another, based on data from clinical trials
Submission: development phase that accounts for the time between when data is submitted to the
FDA and when a drug is officially approved
